doses of semaglutide compound | NextGenRx Pharmacy Troubling Findings in Study of

Obesity 31 , 537544 (2023)

Results from recent trials have demonstrated notably greater reductions in body weight, as illustrated below in the SURMOUNT-3 Phase 3 trial with 25% weight reduction among subjects with GLP-1/GIP and engaged in intensive lifestyle intervention

The drug reaches peak plasma concentration within 24 to 72 hours of injection, so the biology is moving fast even if the scale is not

Trial status (May 2026): Eli Lilly reported positive topline results from the Phase 3 TRIUMPH-1 obesity trial on May 21, 2026, with mean weight reduction of 28.3% at 80 weeks on the 12 mg arm [1][2]

Many people starting weight loss protocols are already deficient

Functional activity of murine intestinal mucosal cells is regulated by the glucagon-like peptide-1 receptor